A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE

BACKGROUND: Anti-TNF therapy is well established in the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Therapeutic effect may wane over time leading to secondary loss of response that can be overcome with dose escalation. Data on rate of secondary loss of response...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Can Assoc Gastroenterol
Autores principales: Elias, E, Oketola, A, Krishnan, S, Singh, H, Targownik, L, Bernstein, C N
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Posters Of Distinction
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512547/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.039
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares